104,410 Shares in Xeris Biopharma Holdings, Inc. $XERS Purchased by Palo Alto Investors LP

Palo Alto Investors LP purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 104,410 shares of the company’s stock, valued at approximately $826,927. Palo Alto Investors LP owned 0.06% of Xeris Biopharma at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of XERS. Royal Bank of Canada increased its position in Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after purchasing an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after buying an additional 3,594 shares in the last quarter. Millennium Management LLC boosted its stake in Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after buying an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP acquired a new position in shares of Xeris Biopharma during the 1st quarter valued at $170,000. 42.75% of the stock is owned by institutional investors.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Steven Pieper sold 27,600 shares of Xeris Biopharma stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $8.52, for a total value of $235,152.00. Following the completion of the transaction, the insider owned 1,366,053 shares of the company’s stock, valued at approximately $11,638,771.56. The trade was a 1.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 90,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.03, for a total transaction of $722,700.00. Following the sale, the insider owned 1,691,126 shares of the company’s stock, valued at $13,579,741.78. This represents a 5.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 271,499 shares of company stock worth $2,038,917. Company insiders own 4.35% of the company’s stock.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock traded down $0.12 during midday trading on Friday, hitting $8.48. The company had a trading volume of 1,027,270 shares, compared to its average volume of 1,856,020. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The business’s 50 day simple moving average is $8.26 and its two-hundred day simple moving average is $6.92. Xeris Biopharma Holdings, Inc. has a 1-year low of $5.25 and a 1-year high of $10.08. The stock has a market cap of $1.55 billion, a PE ratio of -77.09 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The business had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. As a group, equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Barclays raised their price target on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.